News

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...
Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...
Novo Nordisk has a commercial relationship with Economist Impact, a division of The Economist Group. The Economist operates ...
Novo Nordisk on Wednesday posted second-quarter sales broadly in line with expectations, after last week cutting its ...
Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
Novo Nordisk continues to deliver double-digit revenue and profit growth, driven by both its diabetes and obesity drug ...
Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...
Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...
Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...